The early 1950s reveal systemic chemotherapy as a viable, tumor-wide strategy for cancer treatment. Demonstrations of measurable responses in malignant melanoma validate the potential of systemic drugs to shrink tumors and induce meaningful remissions, catalyzing broader trials, combination strategies, and a shift toward non-local control. The period broadens the pharmacologic repertoire beyond mustard derivatives, embraces alkylating and other soluble agents, and nurtures the growing integration of chemotherapy with surgery and multidisciplinary care.